Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19
Marcello Di Nisio, Nicola Potere, Matteo Candeloro, Antonella Spacone, Leonardo Pieramati, Giovanna Ferrandu, Giulia Rizzo, Matteo La Vella, Silvio Di Carlo, Donatella Concetta Cibelli, Giustino Parruti, Marcel Levi, Ettore Porreca
Topics & Concepts
MedicineTocilizumabPartial thromboplastin timeInternal medicineInterquartile rangeGastroenterologyFibrinogenProthrombin timeInterleukin 6Cytokine release syndromeCoagulationImmunologyRheumatoid arthritisCytokineCoronavirus disease 2019 (COVID-19)Infectious disease (medical specialty)DiseaseCOVID-19 Clinical Research StudiesHeparin-Induced Thrombocytopenia and ThrombosisSARS-CoV-2 and COVID-19 Research